[Click eStock] "Celltrion Beats Operating Profit Consensus... Time to Buy"

On the 3rd, Korea Investment & Securities analyzed that it is a buying opportunity for Celltrion, as its operating profit exceeded the consensus.

Researcher Wi Haeju of Korea Investment & Securities stated in a report on the same day, "Celltrion's first-quarter earnings are expected to be 629.6 billion KRW in sales and 213.3 billion KRW in operating profit, representing increases of 14.3% and 49.9% respectively compared to the same period last year," adding, "both figures are expected to surpass the consensus by 9.6% and 22.5% respectively."

Researcher Wi forecasted, "First-quarter biosimilar sales will record the highest amount since establishment," and "the biosimilar supply contract amount to Celltrion Healthcare is expected to increase by 64% year-on-year to 406.4 billion KRW, and total biosimilar sales including finished product sales not reflected in contract disclosures will reach 425.7 billion KRW."

The product with the highest sales proportion is Remsima. In particular, shipments of Remsima SC, which had low shipment performance over the past two years, are expected to increase, leading to an improvement in operating profit.

Researcher Wi said, "As Celltrion embarks on structural reform as a new drug development company, Chairman Seo Jungjin has presented goals such as developing its own pipeline to enter 10 clinical phase 1 trials next year and securing new drug platform M&A," adding, "If Chairman Seo Jungjin's drive is combined with development capabilities, entering clinical trials for 10 pipelines next year is difficult but not impossible."

He continued, "Now is the time to buy," emphasizing, "The factors that caused the stock price decline have been resolved, and compared to the first half catalysts such as strong first-quarter earnings, Uplima's US approval in May, and its launch in July, the valuation attractiveness stands out."

This content was produced with the assistance of AI translation services.